Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Anybody who’s used an inhaler to treat asthma or allergies is familiar with the medicinal aftertaste. That taste is more than an annoyance-it’s a sign that a portion of the drug is going to waste in the back of the throat rather than in the lungs where it’s needed. Battelle Pulmonary Therapeutics-a company spun off in April from Battelle Memorial Institute in Columbus, Ohio-is aiming to deliver inhalable drugs more efficiently with new “electrohydrodynamic,” or EHD, aerosol technology.

EHD devices use voltage, rather than pressure, to create a “soft cloud” of aerosolized drug. The patient inhales the cloud, rather than having aerosol shot into the mouth at a velocity that propels drug particles against the throat. The new company believes EHD technology will be valuable against a number of respiratory diseases and infections, including bronchitis and pneumonia. As TR went to press, the startup had signed two licensing agreements-one to commercialize an anti-viral device-and was working on several other deals.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me